Loading stock data…
DYN
$18.46+0.85 (+4.83%)
Market ClosedLast close May 11
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Dyne Therapeutics, Inc. in the Healthcare sector is trading at $18.46. The stock is currently 26% below its 52-week high of $25.00, remaining 9.8% above its 200-day moving average. Technical signals show neutral RSI of 45 and bearish MACD signal, explaining why DYN maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 45) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$18.46
Potential Upside
5%
Whystock Fair Value$19.38
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus16 analysts
Mean target$38.19+106.9%
Range$16.00 – $50.00
Fundamentals
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, includi...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.25B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.28
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-42.47%
Volume
Today's trading volume
1.16M
Recent News
Dyne Therapeutics (DYN) Upgraded to Buy: Here's What You Should Know
Dyne Therapeutics (DYN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Could Dyne Therapeutics’ (DYN) AMCP Spotlight Reveal How New FDA Leadership May Shape Its Pipeline?
Dyne Therapeutics is scheduled to present at the AMCP 2026 Annual Conference in Nashville on April 14, 2026, highlighting its work in neuromuscular disease therapies. At the same time, the prospect of Dr. Houman Hemmati leading the FDA’s Center for Biologics Evaluation and Research introduces a potential shift in the regulatory framework governing Dyne’s biologics and gene therapy programs. We’ll now examine how the potential CBER leadership change may influence Dyne Therapeutics’ investment...
Clearbridge Small Cap Growth Strategy Added Dyne Therapeutics (DYN) in Q4
ClearBridge Investments, an investment management company, released its “ClearBridge Small Cap Growth Strategy” Q4 2025 investor letter. A copy of the letter can be downloaded here. The Strategy underperformed the Russell 2000 Growth Index in the fourth quarter, after a strong first three quarters of 2025. Market’s overreactions to earnings disappointments in the technology sector and […]
This Biotech Was Quietly Bought Before a $58 Per Share Takeout
This clinical-stage biotech develops oral therapies targeting cancer and inflammatory diseases, with lead candidates in active trials.
Dyne Therapeutics Targets 2026 “Breakout Year” With DMD BLA Plans and DM1 Milestones at Stifel Conference
Dyne Therapeutics (NASDAQ:DYN) executives outlined a slate of 2026 operational and regulatory milestones during a discussion with Stifel, emphasizing plans to transition toward a commercial-stage organization while advancing multiple neuromuscular disease programs. Chief Financial Officer Erick Luc